Skip to content

Evaluation of the Repeated Usage of Systane Ultra Eyedrop

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01051804
Enrollment
57
Registered
2010-01-20
Start date
2009-11-30
Completion date
Unknown
Last updated
2012-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Keywords

Dry eye, Visual Performance

Brief summary

Comparison of two contact lens solutions.

Interventions

Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks

Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or more. * Non contact lens wearer. * Symptomatology as defined below for the Ocular Surface Disease Index (OSDI) questionnaire: * Score ≥13 for OSDI Questionnaire total score; AND * Scores of at least 2 for 2 out of the 6 vision related questions of the OSDI questionnaire * Best visual acuity of 6/9 or better in each eye. * Willingness to adhere to the instructions set in the clinical protocol. * Signature of the subject informed consent form.

Exclusion criteria

* Use of systemic medication which might produce dry eye side effects. * Systemic disease which might produce dry eye side effects. * Active ocular infection. * Use of ocular medication. * Significant ocular anomaly. * Previous ocular surgery * Previous use of Restasis * Any medical condition that might be prejudicial to the study. * The subject, based on their knowledge, must NOT be pregnant or lactating at the time of enrolment. * The subject, based on his/her knowledge, must NOT have an infectious disease (e.g. hepatitis, tuberculosis) or an immunosuppressive disease (e.g. Human Immunodeficiency Virus). * The subject, based on their knowledge, must NOT have diabetes.

Design outcomes

Primary

MeasureTime frame
Improvement in objective vision4 weeks

Secondary

MeasureTime frame
Measurement of tear film evaporation4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026